The share price will increase once the loose retail hands who...

The share price will increase once the loose retail hands who bought in from 2020-2021 when the stock market was in a mania, who don't actually understand the value of the company, the IIH market or how it compares to the larger industry of phase III clinical trial stocks, all sell and leave.

T20 isn't changing, so they aren't the ones holding this down. It is the loose retail hands who bought because sentiment was high, and are now selling because of sentiment being low,

And how can you blame them - if you were to go by retail sentiment on HC and twitter for your decision to stay in IXC, you would guess this company's management was blundering everything, failing catalysts and destroying shareholder capital (the power of a few negative sentiment posters who post 7 times a week will do that - meanwhile, in the world of biotech comparables, management have been strong)

People turning their noses up at a year delay for successful catalysts to be achieved, in the schemes of biotech's, have frankly close to zero experience with investing in biotech's and didn't know what sort of industry they were investing in before putting money on the line.

We have a top management team burning through a bottom quartile comparable biotech staff spend, while achieving catalysts and pushing the company closer to significant catalyst events; Phase III recruitment, and anticipation for trial read out thereafter, with a very well credentialed trial steering committee, with T20 not budging and yet HC users complaining daily with bulk retail selling holding the SP down leading into the most pivotal stage of the company's history where the risk/return has been at the most asymmetric levels,

La Divina Commedia.

*Not financial advice.